Background: The apolipoprotein E (APOE) epsilon4 allele is a well-known risk factor for the development of Alzheimer's disease, but little is known about the association of the epsilon4 allele with incident mild cognitive impairment (MCI).
Objective: Test the hypothesis that the epsilon4 allele is associated with an increased risk of developing MCI.
Methods: More than 600 older Catholic clergy members from the Religious Orders Study without any cognitive impairment at baseline underwent APOE genotyping and detailed annual clinical evaluations for up to 16 years of follow-up (mean: 10.17 years; range: 2-16 years) to document incident MCI and rates of decline in global cognition and 5 cognitive domains (i.e. episodic memory, semantic memory, working memory, perceptual speed and visuospatial abilities).
Results: During up to 16 years of annual follow-up, 339 of 607 persons (56%) developed MCI. In a proportional hazards model adjusted for age, sex and education, the presence of the APOE epsilon4 allele was associated with a 1.4-fold increased risk of incident MCI (hazard ratio: 1.36; 95% CI: 1.04, 1.78). Further, this association persisted in analyses that required MCI to persist for at least one year (hazard ratio: 1.50; 95% CI: 1.05, 2.14). Finally, the epsilon4 allele was associated with an increased rate of decline in global cognition and 4 out of 5 cognitive systems (i.e. episodic memory, semantic memory, working memory and perceptual speed).
Conclusion: The presence of the APOE epsilon4 allele is associated with an increased risk of MCI and a more rapid rate of cognitive decline in old age.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857623 | PMC |
http://dx.doi.org/10.1159/000256662 | DOI Listing |
PLoS One
January 2025
Washington University School of Medicine, NeuroGenomics and Informatics Center, St. Louis, MO, United States of America.
Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer's disease (AD), where longitudinal cohorts measure disease "progression," defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute of Human Behaviour and Allied Sciences, Delhi, India.
Background: ApoE polymorphism especially APOE ε4 play a central role in AD pathophysiology through Aβ-dependent and Aβ-independent neuropathogenic pathway in the Alzheimer's disease.
Method: A cross-sectional study was performed on non diseased and diseased subjects with stroke from outpatient services of Neurology department of Institute of Human Behavior & Allied Sciences (IHBAS), New Delhi (India). Subjects diagnosed with various dementias including Alzheimer's disease, non AD dementias and dementia with Behavior & Psychological symptoms were taken.
Background: Previous studies have shown that carriage of the VEGF 1154A (rs1570360) and the VEGF 2578C (rs699947) alleles may confer a protective effect on the development of Alzheimer's disease (AD). However, it is unknown if these associations are APOE-dependent and whether they can be observed in asymptomatic individuals with varying levels of amyloid pathology. The aim of this study is to determine whether interactions between the APOE ε4 allele, VEGF 1154A, and VEGF 2578C are associated with amyloid load in cognitively unimpaired (CU) older adults.
View Article and Find Full Text PDFBackground: Apolipoprotein ε4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) with females having higher risk than males. Compared with non-carriers, cognitively normal, middle-aged APOE4 carriers have lower cerebral blood flow (CBF) decades before clinical symptoms appear. Early intervention to protect CBF would be critical for APOE4 carriers to mitigate AD progression.
View Article and Find Full Text PDFBackground: Understanding the genetic etiology of Alzheimer's disease (AD) has been a major focus of research in neurodegenerative diseases. Amid the three common allelic variants of the apolipoprotein E (APOE) gene in humans, called APOE ε2, ε3 and ε4, the ε4 allele is the most common genetic risk factor for late-onset AD, being found in 20% of the world population.
Method: We used Event-Related Potentials (ERP) and Event-Related Spectral Perturbation (ERSP) as features for classification of apolipoprotein E ϵ4 (APOE ε4) allele carriers in AD patients and healthy controls.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!